exciplex
Commercial- Indications
- Vitiligo, Psoriasis, Atopic dermatitis, Leukoderma
Company intelligence / Profile preview
Clarteis
Sophia Antipolis, Provence-Alpes-Côte d'Azur, Franceclarteis.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Clarteis develops and manufactures ergonomic, CE-certified, and FDA-approved dermatology medical devices. Its flagship product, exciplex®, is a monochromatic excimer light system for treating localized autoimmune skin conditions such as alopecia areata, vitiligo, psoriasis, atopic dermatitis, and mycosis fungoides. The exciplex® device is approved in over 45 countries worldwide including Europe, USA, Japan, Australia, Mexico, Saudi Arabia, Egypt and UAE.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Device
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Clarteis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clarteis.